Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $11.45

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.27.

Several equities research analysts recently issued reports on the stock. Stephens raised their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Royal Bank of Canada dropped their price target on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday. Citigroup cut their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Evercore ISI raised their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the sale, the insider now owns 92,260 shares in the company, valued at approximately $535,108. This represents a 6.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,169 shares of company stock valued at $639,174. 2.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. First Light Asset Management LLC increased its stake in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc grew its holdings in Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after purchasing an additional 360,201 shares during the period. Millennium Management LLC increased its position in shares of Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA raised its stake in shares of Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after buying an additional 25,000 shares during the period. Finally, Daventry Group LP lifted its position in shares of Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after buying an additional 84,178 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Stock Down 0.2 %

HCAT stock opened at $5.49 on Tuesday. The stock has a market capitalization of $334.07 million, a P/E ratio of -4.07 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 1-year low of $5.35 and a 1-year high of $10.99. The business has a fifty day moving average price of $7.56 and a 200-day moving average price of $7.51.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) EPS. Equities analysts forecast that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.